SEC EDGARJUL 21 min read$GILD

O'Day Daniel Patrick sold $1.9M of GILD

O'Day Daniel Patrick (Chairman & CEO) sold 15,000 shares of GILEAD SCIENCES, INC. (GILD) at an average of $126.29 ($126.09–$127.08, $1.89M total) across 2 trades on 2026-07-01 under a Rule 10b5-1 trading plan.

Original reporting

SEC EDGAR · O'Day Daniel Patrick

Published Jul 2, 2026, 4:00 PM UTC

Analysis

alphai AI DeskAI-generated

Added to alphai Aug 6, 2026, 7:37 AM UTC. Informational, not investment advice.

How this was made

alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About alphai AI Desk Scoring methodology Report an issue

alphai market briefInsider activity

Primary signal

$GILD

Neutral

high confidence

Mentioned

$GILD

Relevance

5/10

alphai data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$GILDNeutralLow

Why it matters

Traders may monitor insider activity as a sentiment input, but the disclosure alone does not change Gilead’s fundamentals or near-term outlook based on the provided text.

Market read

Management selling under a 10b5-1 plan is typically low-signal for fundamentals, so the trading impact is likely modest.

What to watch

10b5-1 plans are pre-scheduled and often reduce the informational content of insider sales; the article provides no reason for the sale beyond the plan.

Relevance 5/10Novelty 3/10Timing: filed 2026-07-02, covering sales executed 2026-07-01

Background

The article is an SEC Form 4 insider transaction report for Gilead Sciences, filed after the CEO executed open-market sales under a pre-arranged 10b5-1 plan.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$GILDNeutralHigh confidence

Context

Gilead CEO O'Day sold about $1.89M of GILD shares via an open-market transaction under a pre-arranged 10b5-1 plan on 2026-07-01.

Expected impact

Likely limited, with any impact more sentiment-driven than fundamental.

Evidence & confidence

The filing is a Form 4 insider transaction with a stated 10b5-1 plan and no accompanying operational or guidance change in the text.

Market effects

Sector

No direct sector read-through; this is company-specific insider trading disclosure.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

A large CEO sale can be interpreted by some traders as a confidence signal, even if executed under a 10b5-1 plan.

Key entities

issuer
Gilead Sciences, Inc.
Subject of the Form 4 insider sale disclosure.
insider
O'Day Daniel Patrick
Chairman & CEO who sold shares under a 10b5-1 plan.

Read at source ← All news

SEP 5

$GILDHighAI 8/10

Gilead Sciences Just Won Its Third FDA Approval in Less Than 4 Months. Is the Stock Still Underrating This Turnaround Play?

Gilead Sciences (GILD) received three FDA approvals in four months, boosting its stock 21% YTD. Recent approvals include Bixlenvo for HIV and Trodelvy for breast cancer. The company expects more approvals, including anito-cel for multiple myeloma by year-end. Gilead's Q2 revenue was $7.6B, up 8% YoY, with strong HIV drug sales. The company raised its dividend to $0.82, yielding 2.15%.

yahoo.com3 min

SEP 3

$GILDHighAI 8/10

Why Is Gilead (GILD) Up 13.6% Since Last Earnings Report?

Gilead Sciences (GILD) shares rose 13.6% since its last earnings report. Q2 2026 saw a narrower adjusted loss of $6.75 per share and revenue growth of 10% to $7.80 billion, driven by HIV portfolio and Trodelvy. GILD raised full-year HIV sales growth guidance to 9-10%.

finance.yahoo.com3 min

SEP 2

$MRKLowAI 8/10

Once-Weekly Oral Combination HIV Pill Shows Promise As Alternative to Daily Treatment

Merck and Gilead Sciences are developing a weekly oral HIV treatment combining islatravir and lenacapavir, both FDA-approved separately. The combination aims to offer an alternative to daily HIV medication.

healthandme.com1 min

SEP 2

$GILDHighAI 9/10

Tablet Regimen for Virologically Suppressed Adults Living with HIV

The FDA approved Gilead Sciences' Bixlenvo, a once-daily single-tablet HIV treatment for virologically suppressed adults. The drug combines bictegravir and lenacapavir, simplifying therapy and reducing pill burden. Clinical trials showed non-inferior viral suppression rates and improved health metrics. Bixlenvo is designed for patients with complex treatment histories or resistance challenges.

geneonline.com2 min

AUG 31

$GILDHighAI 9/10

A new once-daily pill to treat HIV just got the FDA’s green light

The FDA approved Gilead Sciences' once-daily HIV pill, Bixlenvo, for adults with suppressed HIV who cannot use current single-pill treatments. It combines bictegravir and lenacapavir, with a list price of $4,595 per month. Gilead aims to provide more treatment options, especially for older patients with complex regimens. According to the company, this group represents about 5% of HIV patients in the U.S.

advocate.com2 min